By Lars Fruergaard Jørgensen, CEO, Novo Nordisk; EFPIA President, Stefan Oelrich, member of the board of management, Bayer; EFPIA Vice President and David Loew, CEO, Ipsen; EFPIA Second Vice President.

Over the years, Europe’s share of global medicine R&D investments has dropped. However, with the new EU mandate, there is a chance to turn this around.

At the start of the EU’s new mandate, we have the chance to reset the agenda for life sciences. Just imagine if the next generation of therapies were developed right here in Europe. Imagine if they could change the course of public health, helping Europeans to live longer and feel better.

Over the last 20 years, Europe has lost a quarter of its share of global research and development (R&D) investment to other, more ambitious regions like the US and China. We believe now is the time to come together and build a strategy that can help address Europe’s competitiveness challenges in life sciences, while equipping member states with the tools they need to address their health concerns.

Read the full POLITICO article here.